August 8, 2016
A key drug review committee of the Ministry of Health, Labor and Welfare (MHLW) on August 5 recommended approval for a batch of drugs including Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) for an additional indication of renal cell carcinoma (RCC)...read more